Unicycive granted FDA review for kidney disease drug (UNCY)

Core Viewpoint - Unicycive Therapeutics has received acceptance from the FDA for its resubmitted New Drug Application for oxylanthanum carbonate, a therapy aimed at treating kidney disease, following a previous rejection in June [2]. Group 1 - The FDA's acceptance of the NDA marks a significant step for Unicycive Therapeutics in advancing its kidney disease treatment [2]. - The initial rejection of the oral phosphate therapy occurred in late June, indicating prior challenges in the approval process [2].